US14817C1071 - Common Stock
CASSAVA SCIENCES INC
NASDAQ:SAVA (11/25/2024, 12:10:10 PM)
4.7099
-21.77 (-82.21%)
Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. The company is headquartered in Austin, Texas and currently employs 29 full-time employees. The company went IPO on 2000-07-14. The firm's science is based on stabilizing, but not removing, a critical protein in the Alzheimer’s brain. Its scientific approach for the treatment of Alzheimer's disease seeks to simultaneously suppress both neurodegeneration and neuroinflammation. The company has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease dementia. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimer’s brain. The company is conducting two randomized placebo-controlled Phase III clinical trials of oral simufilam in patients with Alzheimer’s disease dementia. SavaDx, its lead investigational diagnostic product candidate, is a way to detect the presence of Alzheimer’s disease from a small sample of blood. SavaDx is a research-use only, non-safety related exploratory biomarker.
CASSAVA SCIENCES INC
6801 N. Capital of Texas Highway, Building 1
Austin TEXAS 78731
P: 15125012444
CEO: Remi Barbier
Employees: 29
Website: https://www.cassavasciences.com/
Which stocks are gapping on Monday?
The company tested simufilam in patients with mild-to-moderate Alzheimer's disease.
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer’s disease in...
Webcast planned for Monday, November 25th at 8:00 AM ET
Here you can normally see the latest stock twits on SAVA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: